Drug Profile
Research programme: tuberculosis therapeutics - Department of Biotechnology/Sun Pharmaceutical Industries
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Department of Biotechnology; Ranbaxy Laboratories
- Developer Department of Biotechnology (India); Sun Pharmaceutical Industries
- Class Small molecules; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis in India
- 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis in India (Parenteral, Injection)
- 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries